Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.
Conditions: Diabetes Mellitus, Type 2; Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; CKD; Proteinuria Interventions: Drug: Dapagliflozin 10mg Tab; Drug: Placebo; Device: Withings BPM Connect; Device: Withings Body+; Diagnostic Test: Hem-Col Capillary Blood Collection Device; Device: MEMS (Medication Electronic Monitoring System) Cap; Behavioral: Questionnaire: participants ' perspectives toward remote data collection Sponsors: University Medical Center Groningen; AstraZeneca Comple...
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Postoperative New-onset Proteinuria and Adverse Outcomes.
Conditions: Surgery; Proteinuria; Mortality Interventions: Other: proteinuria Sponsors: Yaozhong Kong Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
Effect of Ramadan Fasting on Kidney Function and Proteinuria in Patients With Glomerulonephritis
Conditions: Fasting Ramadan Interventions: Behavioral: fasting month of ramadan Sponsors: Alexandria University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)
DiscussionNo effective treatment exists for caAMR at present. Based on the hypothesis that inhibition of IL-6 receptor by tocilizumab will reduce antibody production and reduce antibody-mediated damage, our randomized trial has a potential to provide evidence for a novel treatment strategy for caAMR, therewith slowing the decline in graft function in the long-term.Trial registrationClinicalTrials.gov NCT04561986. Registered on September 24, 2020 (Source: Trials)
Source: Trials - March 22, 2024 Category: Research Source Type: clinical trials
Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies
ConclusionFIONA is evaluating the use of finerenone in children with CKD and proteinuria. Should safety, tolerability, and efficacy be demonstrated, finerenone could become a useful additional therapeutic agent in managing proteinuria and improving kidney outcomes in children with CKD.Trial registrationClinicalTrials.gov NCT05196035. Registered on 19 January 2022. (Source: Trials)
Source: Trials - March 21, 2024 Category: Research Source Type: clinical trials
Renal Impact of KAFTRIO in Mucoviscidose Population
Conditions: Cystic Fibrosis Interventions: Biological: Evaluation of the parameters of the lithiasis assessment before and after KAFTRIO initiation; Drug: Collection of Arterial pressure, metabolic data, kidney function, proteinuria and hematuria before and after KATRIO initiation Sponsors: Hospices Civils de Lyon Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials
Proteinuria in Renal Transplant Patients Treated With Dapagliflozin
Conditions: Chronic Kidney Diseases Interventions: Procedure: Follow-up at D14; Procedure: Follow-up at M1 Sponsors: University Hospital, Montpellier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2023 Category: Research Source Type: clinical trials
ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank
Conditions: Focal Segmental Glomerulosclerosis; Proteinuria; Nephrotic Syndrome; Nephrotic Syndrome Steroid-Resistant Interventions: Other: Registry Sponsors: Christoph Aufricht Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Zibotentan/Dapagliflozin Combination Demonstrated Significant Albuminuria Reduction in Patients with Chronic Kidney Disease and Proteinuria in ZENITH-CKD Phase IIb Trial
52.5% reduction with high-dose and 47.7% reduction with low-dose combination compared to baseline, and an acceptable tolerability profile
Novel investigational drug leverages SGLT2 inhibition and high selectivity ETA receptor antagonism with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 3, 2023 Category: Pharmaceuticals Source Type: clinical trials
PEPPI Study: Identification of Women at Risk for Placental Dysfunction
Conditions: Pre-Eclampsia; Intrauterine Growth Restriction; Polycystic Ovary Syndrome; Iron-deficiency; Cardiovascular Diseases; Hypertensive Disorder of Pregnancy; Proteinuria in Pregnancy Interventions: Other: Pre-eclampsia screening program Sponsors: Oulu University Hospital; PerkinElmer, Inc.; Roche Diagnostics; Academy of Finland; Sigrid Jus élius Foundation; Finnish Medical Foundation; University of Oulu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
Novartis Investigational Atrasentan Phase III Study Demonstrates Clinically Meaningful and Highly Statistically Significant Proteinuria Reduction in Patients with IgA Nephropathy (IgAN)
Phase III ALIGN study met its primary endpoint, demonstrating superiority of atrasentan vs. placebo in proteinuria reduction at 36-week interim analysis1; the safety profile of atrasentan was consistent with previously reported data1,2-4
IgAN... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 30, 2023 Category: Pharmaceuticals Source Type: clinical trials
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
Conditions: Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus, Type 2; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; CKD; CKD Stage 3; CKD Stage 4 Interventions: Drug: Empagliflozin 10 MG; Drug: Finerenone; Device: Withings BPM Connect; Device: Withings Body; Diagnostic Test: PeeSpot Urine Collection Device; Diagnostic Test: Hem-Col Capillary Blood Collection Device; Behavioral: Questionnaire: participants ' perspectives toward the feasibility of parti...
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
Maternal Treatment With ACE-inhibitors and Breastfeeding: a Mono-centric Study on the Exposure Through Breast Milk
Conditions: Breast Feeding; Hypertension; Heart Failure; Proteinuria Interventions: Procedure: Venipuncture Sponsors: Universitaire Ziekenhuizen KU Leuven; KU Leuven Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2023 Category: Research Source Type: clinical trials
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
Conditions: Chronic Kidney Disease With High Proteinuria Interventions: Drug: Zibotentan/Dapagliflozin; Drug: Dapagliflozin Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2023 Category: Research Source Type: clinical trials
Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Highly Statistically Significant Proteinuria Reduction in Patients with IgA Nephropathy (IgAN)
Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan vs placebo in proteinuria reduction1
Iptacopan is an investigational, first-in-class, oral factor B inhibitor... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 2, 2023 Category: Pharmaceuticals Source Type: clinical trials
